Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration
dc.rights.license | open | en_US |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | KOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535 IDREF: 028739272 | |
dc.contributor.author | SCHMIDT-OTT, Ursula Maria | |
dc.contributor.author | SCHULZE, Andrea | |
dc.contributor.author | ZHANG, Xin | |
dc.contributor.author | LEAL, Sergio | |
dc.date.accessioned | 2023-12-19T08:50:42Z | |
dc.date.available | 2023-12-19T08:50:42Z | |
dc.date.issued | 2023-06 | |
dc.date.conference | 2023-04-23 | |
dc.identifier.issn | 0146-0404 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/186717 | |
dc.description.abstractEn | Purpose : In PULSAR (NCT04423718), the primary endpoint of change from baseline in best-corrected visual acuity at Week 48 (non-inferiority margin at 4 letters) was met with intravitreal aflibercept 8 mg every 12 or 16 weeks (8q12 or 8q16) vs aflibercept 2 mg every 8 weeks (2q8). Here, we report safety and tolerability through Week 48. Methods : PULSAR is an ongoing, double-masked, 96-week, Phase 3 trial. Patients aged ≥50 years with treatment-naïve neovascular age-related macular degeneration (nAMD) were randomly assigned 1:1:1 to 8q12, 8q16 or 2q8, each after three initial monthly injections. Results : Of 1,009 patients (mean age 74.5 years) randomly assigned and treated (2q8: n=336; 8q12: n=335; 8q16: n=338), 11 (1.1%) discontinued with adverse events (AEs) as the primary reason. In the 2q8, 8q12 and 8q16 groups, 46/336 (13.7%), 34/335 (10.1%), and 32/338 patients (9.5%) had treatment-emergent (TE) non-ocular serious AEs, respectively; adjudicated Antiplatelet Trialists’ Collaboration (APTC) events occurred in 1.5%, 0.3%, and 0.6%, respectively. In total, 38.3% of patients experienced at least one TE ocular AE in the study eye (2q8: 130/336 [38.7%]; 8q12: 129/335 [38.5%]; 8q16: 127/338 patients [37.6%]); most common were reduced visual acuity (6.0%, 3.6%, 5.3% for 2q8, 8q12 and 8q16, respectively), cataracts (3.0%, 3.6%, and 3.6%, respectively), and retinal hemorrhage (4.2%, 3.3%, and 3.0%, respectively). Pre-injection intraocular pressure (IOP) values were similar to baseline at all timepoints through Week 48. The proportion of patients with pre- or post-dose IOP ≥35 mmHg was similar in 2q8, 8q12 and 8q16 groups (0.3%, 0.9%, and 0.3%, respectively). Seven patients had intraocular inflammation (IOI; 2q8: 0.6%; 8q12: 1.2%; 8q16: 0.3%), none discontinued and there were no cases of endophthalmitis or occlusive retinal vasculitis. In all groups, proportions of patients with TE anti-drug antibody (ADA)-positive status were very low and consistent with rates previously reported for aflibercept 2 mg. Conclusions : The safety profile of aflibercept 8 mg was similar to that of aflibercept 2 mg through Week 48 in patients with nAMD. Of note, rates of APTC events, IOI and TE ADA-positivity were very low; IOI was not associated with positive ADA status. This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023. | |
dc.language.iso | EN | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.title.en | Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration | |
dc.type | Communication dans un congrès | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
bordeaux.volume | 64 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 8 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.conference.title | The Beauty of Diversity in Science and Nature | en_US |
bordeaux.country | us | en_US |
bordeaux.team | LEHA_BPH | en_US |
bordeaux.conference.city | New Orleans | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-04352473 | |
hal.version | 1 | |
hal.date.transferred | 2023-12-19T08:50:44Z | |
hal.proceedings | Oui | |
hal.conference.end | 2023-04-27 | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2023-06&rft.volume=64&rft.issue=8&rft.eissn=0146-0404&rft.issn=0146-0404&rft.au=KOROBELNIK,%20Jean-Francois&SCHMIDT-OTT,%20Ursula%20Maria&SCHULZE,%20Andrea&ZHANG,%20Xin&LEAL,%20Sergio&rft.genre=unknown |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |